Director/PDMR Share Dealings

Press Release www.shire.com Director/PDMR Share Dealings May 1, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces itwas notified today that on April 30, 2015, Stock Appreciation Rights ("SARs")and Restricted Stock Units ("RSUs") were granted to Persons DischargingManagerial Responsibilities ("PDMRs") under the Shire Long Term Incentive Plan2015 ("LTIP"). SARs and RSUs will normally vest after three years, subject toany performance conditions being satisfied, with no consideration payable onthese awards. The awards were granted over notional American Depositary Shares("ADSs") in the Company as follows: PDMR Type of Award Number of ADSs Exercise Price (1),(2) (3) Flemming Ornskov SAR 26,398 $245.48 RSU 19,799 Nil Jeff Poulton SAR 8,862 $245.48 RSU 6,646 Nil Mark Enyedy SAR 4,444 $245.48 RSU 4,191 Nil Ginger Gregory SAR 4,259 $245.48 RSU 4,016 Nil Phil Vickers SAR 4,259 $245.48 RSU 4,016 Nil 1. SARs and RSUs granted under the LTIP correspond to SARs and Performance Share Awards ("PSAs") granted under the legacy Shire Portfolio Share Plan, as referenced in the Directors' Remuneration Report in the 2014 Annual Report and Accounts. 2. SARs and RSUs granted to Dr. Ornskov and Mr. Poulton and RSUs granted to the remainder of the PDMRs are subject to performance conditions. Upon normal vesting, any ADSs to be delivered to Dr. Ornskov and Mr. Poulton will be subject to a retention period of two years in accordance with the rules of the LTIP. 3. One ADS is equal to three Ordinary Shares of 5 pence each in the Company. This notification is to satisfy the Company's obligations under 3.1.4(R)(1)(a)of the Disclosure and Transparency Rules. Tony GuthrieDeputy Company Secretary For further information please contact: Investor RelationsSarah Elton-Farr [email protected] +44 1256 894157 NOTES TO EDITORS Shire enables people with life-altering conditions to lead better lives. Our strategy is to focus on developing and marketing innovative specialtymedicines to meet significant unmet patient needs. We focus on providing treatments in Rare Diseases, Neuroscience,Gastrointestinal and Internal Medicine and we are developing treatments forsymptomatic conditions treated by specialist physicians in other targetedtherapeutic areas, such as Ophthalmics. www.shire.com Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX